Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00302471 | MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) | PHASE1 | COMPLETED | 29 | — | — | Mar 1, 2006 | Oct 1, 2007 | Apr 27, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1600 mg twice a day | EXPERIMENTAL | MK0429 |
| 200 mg twice a day | EXPERIMENTAL | MK0429 |
| 800 mg twice a day | EXPERIMENTAL | MK0429 |
| 400 mg twice a day | EXPERIMENTAL | MK0429 |
| Name | Type | Description |
|---|---|---|
| Comparator: MK0429 | DRUG | Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone. Disease. |
Inclusion Criteria: * Eligible patients must have: * Prostate cancer * Bone metastases without symptoms * Lack of response to hormone therapy as evidenced by a rising PSA or clinical progression Exclusion Criteria: * Prostate cancer-related bone pain * Previously received bisphosphonate th...